EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The role of the glucagon‐FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition

Maria Moreno-Lopez, Isaline Louvet, Nathalie Delalleau, Ana Acosta-Montalvo, Julien Thevenet, Gianni Pasquetti, Valery Gmyr, Julie Kerr-Conte, Francois Pattou, Caroline Bonner iD, Chiara Saponaro iD

Diabetes, Obesity and Metabolism · 2025-02 · 27 (2) · 885-898

DOI: 10.1111/dom.16089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 01.12.2024. Verfasst von Maria Moreno-Lopez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Lille, CHU Lille, Inserm U1190, EGID, Institut Pasteur de Lille, Lille, France. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Glucagon, Glucose Intolerance, Insulin-Secreting Cells. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Consortium for Islet Transplantation by the Juvenile Diabetes Research Foundation, European Genomic Institute for Diabetes, Société Francophone du Diabète 2015 Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Although primarily secreted by the liver, Fibroblast Growth Factor 21 (FGF21) is also expressed in the pancreas, where its function remains unclear. This study aims to elucidate the role of the glucagon‐FGF21 interaction in the metabolic benefits of SGLT2 inhibition (SGLT2i) and hypothesizes it is key to enhancing glucose and lipid metabolism in individuals with glucose intolerance or type 2 diabetes (T2D).

Methods

FGF21 , FGF1R, and β‐klotho expression in human pancreas was analysed by RNAscope, qPCR and immunofluorescent techniques. Glucose‐stimulated insulin secretion (GSIS) assay was used to investigate the effects of recombinant FGF21 (rFGF21) on islets from donors with glucose intolerance or T2D. To explore the role of the glucagon‐FGF21 axis in the benefits of SGLT2i, we used WT and Sglt2 knockout (KO) mice fed a chow diet (CD) or a high‐fat diet (HFD) and chronically treated with vehicle or dapagliflozin.

Results

Chronic rFGF21 treatment enhanced GSIS in islets from donors with glucose intolerance, with increased FGFR1 expression, suggesting FGF21's greater efficacy in the early stages of disease. In diet‐induced insulin‐resistant mice, dapagliflozin reduced postprandial glycaemia and elevated plasma glucagon and FGF21 levels. Sglt2 KO mice on a CD showed increased fasting plasma glucagon without changes in FGF21. In diet‐induced insulin‐resistant Sglt2 KO mice, elevated glucagon and FGF21 levels paralleled chronic dapagliflozin treatment, indicating similar metabolic adaptations in both models.

Conclusion

Our findings indicate FGF21 as a crucial mediator in liver‐pancreas crosstalk, improving lipid and glucose metabolism, enhancing pancreatic function, and potentiating the therapeutic efficacy of SGLT2i, thereby representing a target for prediabetes treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibroblast Growth FactorsGlucagonGlucose IntoleranceInsulin-Secreting CellsSodium-Glucose Transporter 2 InhibitorsMice, KnockoutDiabetes Mellitus, Type 2GlucosidesAnimalsHumansMiceMaleBenzhydryl CompoundsInsulin SecretionFemaleDiet, High-FatMice, Inbred C57BLKlotho Proteins

Stichwörter der Autor:innen

FGF21SGLT2 inhibitionglucagonglucose intolerancehuman isletstype 2 diabetes

Substanzen

Fibroblast Growth FactorsGlucagonSodium-Glucose Transporter 2 Inhibitorsfibroblast growth factor 21GlucosidesBenzhydryl CompoundsdapagliflozinKlotho ProteinsFGF21 protein, human

Autor:innen und Institutionen

  • Univ. Lille, CHU Lille, Inserm U1190, EGID, Institut Pasteur de Lille, Lille, France.

ORCID-Profile: Caroline Bonner, Chiara Saponaro

Förderung

  • European Consortium for Islet Transplantation by the Juvenile Diabetes Research Foundation
  • European Genomic Institute for Diabetes
  • Société Francophone du Diabète 2015 Award
  • EFSD/Lilly 2016
  • PRECIDIAB Ph.D. thesis stipend
  • EFSD/Lilly Young Investigator Research Award 2021
  • European Foundation for the Study of Diabetes

Zitieren

APA

Moreno-Lopez, M., Louvet, I., Delalleau, N., Acosta-Montalvo, A., Thevenet, J., Pasquetti, G., Gmyr, V., Kerr-Conte, J., Pattou, F., Bonner, C., & Saponaro, C. (2025). The role of the glucagon‐FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition. Diabetes, Obesity and Metabolism, 27(2), 885-898. https://doi.org/10.1111/dom.16089

Vancouver

Moreno-Lopez M, Louvet I, Delalleau N, Acosta-Montalvo A, Thevenet J, Pasquetti G, et al. The role of the glucagon‐FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition. Diabetes, Obesity and Metabolism. 2025;27(2):885-898. doi:10.1111/dom.16089

BibTeX
@article{MorenoLopez2025,
  author = {Moreno-Lopez, Maria and Louvet, Isaline and Delalleau, Nathalie and Acosta-Montalvo, Ana and Thevenet, Julien and Pasquetti, Gianni and Gmyr, Valery and Kerr-Conte, Julie and Pattou, Francois and Bonner, Caroline and Saponaro, Chiara},
  title = {The role of the glucagon‐FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {2},
  pages = {885--898},
  doi = {10.1111/dom.16089}
}
Kostenlos starten →